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"Medicine is a science of uncertainty and an art of probability." 
William Osler 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my family 
 4 
CONTENTS 
HIGHLIGHTS	  ..........................................................................................................................	  6	  
LIST	  OF	  PAPERS	  ....................................................................................................................	  7	  
ABBREVIATIONS	  ..................................................................................................................	  8	  
ABSTRACT	  ..............................................................................................................................	  9	  
AGING	  ....................................................................................................................................	  10	  ELDERLY	  AND	  LIFE	  EXPECTANCY	  ....................................................................................................	  10	  
THE	  OLD	  AGE	  PROBLEM	  .................................................................................................	  12	  
DIFFERENCES	  BETWEEN	  THE	  YOUNG	  AND	  OLD	  ....................................................	  14	  
THE	  AGING	  HEART	  ...........................................................................................................	  16	  
CORONARY	  ARTERY	  DISEASE	  IN	  THE	  ELDERLY	  .....................................................	  17	  THE	  IMPACT	  OF	  CORONARY	  ARTERY	  DISEASE	  ...............................................................................	  17	  ACS	  CAN	  MANIFEST	  DIFFERENTLY	  IN	  THE	  ELDERLY	  ...................................................................	  17	  AGE	  RELATED	  INEQUALITIES	  IN	  ACS	  CARE	  (PAPER	  I)	  ................................................................	  18	  
MEDICAL	  TREATMENT	  FOR	  ACS	  ..................................................................................	  21	  ASPIRIN	  ................................................................................................................................................	  22	  THIENOPYRIDINES	  .............................................................................................................................	  22	  BETA-­‐BLOCKERS	  .................................................................................................................................	  23	  ACE-­‐I	  ...................................................................................................................................................	  23	  STATINS	  ...............................................................................................................................................	  24	  
CONSERVATIVE	  OR	  INVASIVE	  TREATMENT	  ............................................................	  25	  SELECTION	  OF	  TREATMENT	  METHOD	  IN	  THE	  ELDERLY	  (PAPER	  II)	  ..........................................	  25	  
UNTANGLING	  CLINICAL	  COMPLEXITY	  .......................................................................	  28	  PROGNOSIS	  AND	  LIFE	  EXPECTANCY	  ................................................................................................	  29	  
EVALUATING	  RISK	  IN	  THE	  ELDERLY	  ..........................................................................	  30	  AGE	  RELATED	  RISK	  .............................................................................................................................	  31	  COMPETING	  RISK	  ................................................................................................................................	  31	  DISEASE	  RELATED	  RISK	  .....................................................................................................................	  33	  TREATMENT	  RELATED	  RISK	  .............................................................................................................	  33	  RISK	  RELATED	  TO	  THERAPY	  IN	  STEMI	  PATIENTS	  (PAPER	  III)	  ................................................	  35	  
EVALUATING	  BENEFIT	  TO	  THE	  ELDERLY	  POPULATION	  .....................................	  38	  PROGNOSTIC	  INDICATION	  .................................................................................................................	  38	  SYMPTOM	  INDICATION	  ......................................................................................................................	  39	  
SHARED	  DECISION	  MAKING	  ..........................................................................................	  41	  TOO	  RISKY	  OR	  SIMPLY	  TOO	  OLD?	  .....................................................................................................	  42	  UPCOMING	  STUDIES	  ...........................................................................................................................	  43	  
 5 
THE	  OCTOGENARIANS	  STUDY	  (PAPER	  IV)	  ....................................................................................	  43	  
HIGH	  RISK	  GROUPS	  ..........................................................................................................	  45	  CARDIOGENIC	  SHOCK	  .........................................................................................................................	  45	  CARDIAC	  ARREST	  (PAPER	  V)	  ...........................................................................................................	  46	  
CHALLENGES	  IN	  GERIATRIC	  RESEARCH	  ....................................................................	  51	  PATIENT	  SELECTION	  AND	  RISK	  FOR	  BIAS	  .......................................................................................	  51	  PATIENT	  RECRUITMENT	  ....................................................................................................................	  52	  CHALLENGING	  DATA	  ANALYSIS	  AND	  INTERPRETATION	  OF	  RESULTS	  ........................................	  53	  
AGE	  IS	  OPPORTUNITY	  .....................................................................................................	  54	  
ACKNOWLEDGEMENTS	  ...................................................................................................	  55	  
SWEDISH	  SUMMARY	  ........................................................................................................	  56	  
REFERENCES	  .......................................................................................................................	  58	  
 6 
HIGHLIGHTS  
• The elderly are currently the fastest growing segment of clinical 
practice and data are needed to adequately counsel patients so 
that their expectations are aligned with their likely outcomes. 
• Making the diagnosis acute coronary syndrome (ACS) in the 
elderly is not always a simple task 
• The quality and quantity of the underlying scientific evidence is 
limited making it problematic for clinicians to evaluate benefit 
and risk from treatment in the elderly, but this fact alone should 
not result in treatment being withheld 
• Elderly remain a challenging patient group in research and 
results from geriatric studies may be difficult to interpret. 
• Aging seldom comes alone, often being accompanied by chronic 
diseases, comorbidity, disability, and frailty. 
• The principal barrier in recommending medical or invasive 
therapy to elderly patients with ACS is their greater perceived 
risk, explaining an undertreatment compared to their younger 
counterparts. 
• A universal, one-size-fits all, therapy approach is unlikely to be 
successful in the total cohort of elderly patients with ACS. A 
more reasonable treatment approach would be an individualized 
one, taking into consideration: life expectancy, risk, benefit and 
patient preferences. 
• Future investigations should continue to challenge age-related 
discrimination, demanding rigorous investigation into the factors 
that impair quality and quantity of life. 
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ABSTRACT 
The elderly are currently the fastest growing segment of clinical practice but the 
quality and quantity of the underlying scientific evidence to guide treatment is 
limited. In this thesis five individual studies investigating aspects of geriatric 
cardiac care are presented.  
In Paper I, a study of age related differences in patients with symptoms 
suggestive of acute coronary syndrome (ACS) showed that elderly patients 
(>80 years) were more likely to receive a final diagnosis of ACS but were less 
often investigated with coronary angiogram or echocardiography than their 
younger counterparts. Elderly with ACS received less medical treatment with 
P2Y12 antagonists and lipid lowering drugs. Elderly with chest pain could not 
be shown to have a delay to hospital admission compared to their younger 
counterparts. These findings underscore the substantially more complex 
comorbidities and worse outcome among elderly patients who were less likely 
to receive evidence based treatment.  
In Paper II, the differences between elderly (>75years) patients with myocardial 
infarction selected for invasive or conservative treatment strategy were 
investigated. Heart failure, both previous history and at presentation, turned out 
to be more common in the conservative group compared to the invasive group. 
There was lower mortality in the invasive group (in-hospital 9% vs. 20%, 
p<0.0003) compared to the conservative group. Although it is tempting to 
attribute the apparently lower mortality rate to the invasive treatment strategy 
such a causative assumption cannot be made due to the observational study 
design and should be confirmed by a randomized clinical trial (such as 
described in Paper IV). 
In Paper III, elderly STEMI patients treated with PCI were investigated during 
a 10-year study period. During the study period, average age and co-morbidity 
increased, but the procedural success and prognosis remained constant. In 
addition, risk, in terms of bleeding, re-infarction, heart failure and stroke 
remained similar during the study period.  
In Paper V, elderly patients (>70 years) who suffered OHCA were stratified in 
3 different age groups: 70-79, 80-89 and ≥90 years of age. With increasing age 
the 30-day survival decreased. However, even in patients above 90 years of 
age, defined subsets with a survival rate of more than 10% exist. In survivors, 
age was not a key determinant for bad neurological outcome.                                                  
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AGING 
 
"Old age is the most unexpected of all things that can happen to a man." 
-Leon Trotsky 
 
 
Aging is defined as the process of becoming older. It represents the changes in 
the human body with time. There occur multiple changes with time, both 
psychological and physiological.  
Age is measured chronologically depending on a persons birthdate, but there 
exists a more physiological term, referred to as biological age. Although 
biological age is used in the clinical setting it turns out to be observer 
dependent. There have been evolved different methods to determine biological 
age, but these methods are not practical as they require measurements of 
multiple biomarkers1 and/or genetic testing.2 
Aging is individualized and multidimensional. There exists extreme 
heterogeneity among the group of aged. The medical, physiologic, 
psychological, and cognitive changes of aging are poorly reflected in 
chronologic age and can be best appreciated with a multidimensional 
assessment of the older person. 
 
Elderly and life expectancy 
There exist various definitions of old age or elderly, which explains the 
inconsistency in the research setting. The term elderly is defined officially by 
the World Health Organization (WHO) as chronological age 65 years, but this 
applies for western countries. In the continent of Africa the age 50-55 years is 
sufficient to be considered elderly, due to the much lower life expectancy. The 
United Nations criterion for old age and elderly is 60 years. 
In the scientific world, different definitions exist to describe the group of 
elderly. In the American Heart Association (AHA) guidelines from 2002 for 
management of ACS >75 years patients were categorized as a special at-risk 
group. In 2007, an AHA scientific statement3 recommended the use of age cut 
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points based on the average population age, such as <65, 65-75, 75-85 and 
above 85 years for studies of the elderly in western countries. 
Some other definitions exist such as Octogenarians describing those over 80 
years old, Nonagenarians >90 years old and finally, Centenarians >100 years 
old.  
Life expectancy varies in the different countries. Some African countries may 
have a life expectancy of only around 55 years of age, while in the developed 
countries the life expectancy is much higher and is on the increase.4 In Sweden, 
the mean life expectancy at birth is around 84 years for women and 80 years for 
men but is increasing (figure 1). The main explanation for the temporal trend of 
increasing life expectancy in developed countries is medical innovations and 
advances leading to extended life.  
 
Figure 1. Life expectancy at birth by sex in 1960-2013 and forecast 2014-2060 in Sweden. 
Statistics Sweden. www.scb.se 
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THE OLD AGE PROBLEM 
"All diseases run into one, old age."  
-Ralph Waldo Emerson 
 
Population aging is the increase in the number and proportion of the elderly in a 
country. According to the United Nations World Population Report5 globally, 
the number of older persons (aged 60 years or over) is expected to more than 
double, from 841 million people in 2013 to more than 2 billion in 2050. 
Population aging is primarily due to lower child and adult mortality in 
combination with lower fertility rates.  
The problem of old age will not go away, it will only escalate. Problems related 
to aging, multimorbidity, and polypharmacy have become a prominent issue in 
global healthcare. Under the past years it has been realized that as the 
population ages, health care consumers also increase rapidly with major 
economic and social consequences. Another alarming fact is that the old-age 
support ratio (number of working-age adults per older person in a population) is 
declining meaning fewer individuals supporting social security systems with 
increasing demand for resources. Preparation and prioritizing is needed to meet 
these demands of elderly individuals in the future. In the most utopic sense this 
should be done by fulfilling the ethical principles of beneficence and non-
maleficence, or do not harm, without any age-discrimination. But a strong 
evidence base will be needed in order to do so.  
Policymakers face the challenge of understanding and managing future health 
care costs. In a systematic review of health care utilization in the elderly 
population, with each additional chronic condition a linear or near exponential 
relationship was found in the use and cost of health care.6 
Medical advances have lead to some extremely expensive technologies in 
cardiology such as left ventricular assist devices and intraventricular 
cardioverter defibrillators. With the increasing number of elderly individuals 
there will be large populations with indications for such therapies in the future.  
Cost-effective analysis7 in elderly individuals  will probably reveal therapies 
with high cost and lower effectiveness compared to the younger population. 
The concept of Quality Adjusted Life Year (QALY) has been introduced in 
order to measure disease burden taking into consideration the quality and 
quantity of life lived.8 One concern is that it does not take into account equity 
issues such as the overall distribution of health states - younger, healthier 
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cohorts have many times more QALYs than elderly individuals with co-morbid 
diseases. As a result, QALY analysis may undervalue treatments that benefit 
the elderly or others with a lower life expectancy.  
Techniques that preserve life can prolong an inevitable death, at the risk of 
diminishing quality of life and personal dignity. As we add years of life we may 
be adding years with disabilities. The aging of global populations is the main 
reason for the increase in years lived in disability.9 Saving patients from what 
before was a fatal disease, such as stroke, typically increases those with 
functional disabilities in the community. In qualitative studies of end-of-life 
decision making one of the most important issues for the elderly is being able to 
return to their valued daily activities.10,11 The ultimate goal of the future should 
not only be prolonging life, but also prolonging health. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Elderly Common Diseases in word collage. Image by Mypokcik. 
<www.shutterstock.com> 
 14 
DIFFERENCES BETWEEN THE YOUNG AND OLD 
 
"It is not our differences that divide us. It is our inability to recognize, accept, 
and celebrate those differences." 
-Audre Lorde 
 
 
 
 
 
 
 
 
 
Figure 3. With aging progressive physiological changes occur. Downloaded from 
www.google.com (reuse labeled).  
 
There exist important differences between the young and old. With age, 
progressive physiological changes occur that lead to decline in function of 
organ systems. Another term sometimes used is organ reserve decreases. As a 
result, the capacity of older adults to recover after an illness can be significantly 
affected. One example of decreased organ reserve would be renal function, 
which declines progressively with age, explaining why age is one of the values 
needed to calculate the estimated glomerular filtration rate.12 
Also, there is increased prevalence of co-morbid diseases increasing the 
heterogeneity in the group of elderly. Increased co-morbidity commonly leads 
to polypharmacy.  
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Frailty is important from a clinical point of view, because it constitutes a 
condition of greater risk of adverse outcomes, such as less mobility, less 
independence, hospitalization, disability, and death.13 Frailty is concept in the 
old, but unfortunately the exact definition is lacking14 making it difficult to 
estimate the prevalence. There are multiple manifestations of frailty but no 
single manifestation is sufficient to be considered frail. Most authors agree that 
frailty can be defined as a physiologic state of increased vulnerability to 
stressors that results from decreased physiologic reserves. Physical frailty can 
be estimated with different scales, for example with the Fried Frailty Index 
(FFI) that requires the presence of three or more of the following five 
components: weight loss, exhaustion, weakness, slowness, and low physical 
activity. According to a systematic review15 the prevalence of frailty in the 
community dwelling population of elderly (>65 years) turned out to be around 
10% but in the hospital or nursing home setting the percentage is higher.  
In a recent study investigating the prognostic value of geriatric conditions 
(frailty, physical disability, instrumental disability, cognitive impairment, and 
co-morbidity) frailty turned out to capture most of the prognostic information 
after ACS.16 
Ethical values may change with increasing age. Studies show that younger 
patients prefer a more active stance in medical decision making than older 
patients or that medical preferences change with increased age. One survey 
showed that preferences for active involvement increased until 45 years of age, 
and then declined with age.17 
In general, the same principles do not necessarily apply for the younger as do 
for the older. This is the main reason for why dedicated studies to the elderly 
are important in order to assess risk and benefit.  
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THE AGING HEART 
 
 
 
 
 
"Everyone is the age of their heart." 
-Guatemalan Proverb 
 
Figure 4. 3D rendered illustration of the human vascular system. Image by Sebastian Kaulitzki. 
<www.shutterstock.com> 
Many physicians have very little formal training in geriatric medicine and find 
it difficult to distinguish between normal aging and disease states. 
In the heart, there occur important physiological changes associated with age. 
The net effect of these changes result in decreased exercise tolerance and 
increased vascular resistance.18 The more important changes associated with 
aging of the cardiovascular system are: Firstly, compliance in the 
cardiovascular system decreases with age leading to risk for higher blood-
pressure and diastolic dysfunction of the left ventricle. Secondly, loss of 
myocytes occurs with age leading to hypertrophy of the remaining cells. 
Thirdly, calcification of the valves and conduction system occurs. Fourthly, due 
to changes in the sarcoplasmic reticulum Ca2+ ATP-ase pump myocardial 
relaxation slows, adding to the risk for diastolic dysfunction.  
The etiology for cardiovascular aging is under study, but the proposed 
mechanisms have been; cumulative changes in gene expression, mitochondrial 
dysfunction, non-enzymatic glycation and inflammation. More recently, 
mitochondrial dysfunction is getting more central to theories of aging, because 
age-related changes of mitochondria are likely to impair a host of cellular 
physiological functions contributing to the development of age-related 
diseases.19,20 In experimental rodent models several pharmacological and 
genetic manipulations related to mitochondria and aging are being studied,21,22 
but no such therapy has been approved in men. 
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CORONARY ARTERY DISEASE IN THE ELDERLY 
The impact of coronary artery disease  
The prevalence of coronary artery disease (CAD) increases with age. ACS 
refers to a spectrum of clinical presentations ranging from those for ST-
segment elevation myocardial infarction (STEMI) to presentations found in 
non–ST-segment elevation myocardial infarction (NSTEMI) or in unstable 
angina. It is almost always associated with rupture of an atherosclerotic plaque 
and partial or complete thrombosis of the infarct-related artery. With increasing 
age there is a shift to more patients presenting with NSTEMI and less with 
STEMI or unstable angina.23 
The leading cause of mortality in developed countries is coronary artery disease 
and ACS.24,25 Nevertheless, in most European countries, coronary heart disease 
mortality rates have continued to decrease in younger adults at similar or 
greater rates when compared with older age groups26 and are now less than half 
what they were in the 1980s.27 This reduction in mortality is due to several 
factors the most important ones being the reduction of modifiable risk factors, 
with the exception of diabetes and obesity, and advances that have occurred in 
treatment. 
ACS can manifest differently in the elderly 
Elderly patients may not report symptoms that they consider to be part of 
normal aging, such as dyspnea, fatigue or functional decline. 
Unusual manifestations of disorders, such as ACS, are common in the elderly. 
The diagnostic approach to suspected ACS includes three major components:  
1. clinical profile or symptoms, 2. ECG and 3. cardiac biomarkers (most widely 
used Troponins). But all of these three factors can be difficult to evaluate in 
elderly patients. 
Atypical symptoms (no chest pain) commonly occur in elderly with ACS, such 
as: dyspnea, diaphoresis, nausea or vomiting and syncope. With increasing age, 
the risk for atypical presentation increases and was found to be 43% in a group 
of patients >75 years of age.28 Even in a group of STEMI patients, with most 
likely an occluded coronary artery, chest pain at presentation occurred in only 
57% of those ≥ 85 years of age compared to 90% in the younger cohort (<65 
years).29 ACS patients that present without chest pain are at risk for delays in 
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seeking medical attention, receive less aggressive treatments and have high in-
hospital mortality.30  
In elderly patients, the ECG can be more difficult to interpret due to higher 
incidence of baseline ECG changes such as right or left bundle branch block, 
non-specific ST-deviations or pacemaker rhythm.31,32 
The cardiac troponins are more often elevated in the elderly in the absence of 
ACS, which could add further to the uncertainty of whether or not the patient 
has myocardial infarction. The main reasons explaining the elevated troponins, 
in patients without myocardial infarction are: impairment of renal function, 
arrhythmias and diastolic and/or systolic heart failure. When assessing the high 
sensitive troponin (hsTnT) the optimal cut-off value to distinguish elderly 
patients (>70 years) with or without acute myocardial infarction turned out to 
be around 4-5 times higher than the cut-off value in a younger cohort.33 Hence, 
the risk for a false positive result in elderly individuals would be higher if a 
general (for all age groups) cut-off value is used.  
These aforementioned factors may cloud the clinical picture and prevent a 
timely diagnosis of ACS.  
 
Age related inequalities in ACS care (Paper I) 
Realizing the difficulties in diagnosing ACS in the elderly population one 
would expect delay and undertreatment of elderly patients seeking with 
symptoms suggestive of ACS. To answer such a question, if inequality or delay 
exists, one would need a group of consecutively included patients, in all ages, 
captured early in the ambulance or hospital phase.  Consecutive inclusion, 
during a defined time period, would eliminate the risk for selection bias and 
increase the external validity of the study, as all patients seeking during that 
period are included. Such a study is Paper I.34 
The aim of Paper I was to explore the differences between elderly and younger 
patients seeking with symptoms suggestive of ACS. More specifically, time to 
treatment, admission and diagnostic tests were registered in order to evaluate 
delay time.  
All patients with chest pain who were admitted to a hospital in the Gothenburg 
area were included consecutively over a 3-month period in year 2008. They 
were divided into an elderly group (≥ 80 years) and a reference group (< 80 
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years). Previous medical history, ECG findings, treatments, diagnostic tests, 
and delay times were registered.  
The elderly group consisted of 478 patients presenting with chest pain with a 
mean age ± SD of 86 ± 4 years (range 80–103). The reference group consisted 
of 2110 patients with a mean age ± SD of 54 ±16 years (range 16–79). 
In table 1, showing comparison of hospitalized patients, there were no 
significant differences in delay time to hospital ward admission, to first medical 
therapy with aspirin, or to investigation with coronary angiography (CA) 
between the two groups (elderly and reference). The elderly patients had a 
significantly shorter median time from first medical contact to first ECG (12 vs. 
14 minutes, p=0.002) but after adjustment for confounding factors, especially 
mode of transport, the opposite was found to be the case (p=0.002).  
Elderly patients were more likely to receive a final diagnosis of ACS (17% vs. 
8%) than their younger counterparts. Elderly hospitalized patients with ACS 
were less often investigated with CA (44% vs. 89%, p<0.0001). Elderly with 
ACS received less medical treatment with P2Y12 antagonists and lipid lowering 
drugs. One-year mortality in hospitalized patients was 26% in the elderly 
group, compared to 4% in the reference group. 
The conclusions of Paper I are the following: Elderly individuals with 
symptoms suggestive of ACS could not be shown to have a delay to hospital 
admission compared to their younger counterparts, but elderly with ACS 
received less medical treatment and diagnostic investigations (coronary 
angiography and echocardiography). These findings underscore the 
substantially more complex comorbidities and worse outcome among elderly 
patients who were less likely to receive evidence based treatment.  
 
Table 1. Shown on the next page (20): Delay variables in patients above and below the 
age of 80 years, with symptoms suggestive of ACS 
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MEDICAL TREATMENT FOR ACS 
 
 
 
 
 
 
 
 
Figure 5. Many pills and tablets isolated on white background. Photo by Photostock 10. 
<www.shutterstock.com> 
The aims of therapy for coronary artery disease are to prevent further episodes 
of myocardial ischemia and doing so, controlling symptoms and decreasing 
morbidity and mortality.  
In general, the evidence to support medical therapy in older adults is less robust 
than in their younger counterparts, especially in individuals >75 years of age.  
The following medications are those most widely used in patients with ACS 
and are recommended in the guidelines,35 in the absence of contraindications. 
In the elderly, a tailored approach to medical therapy might be needed due to 
polypharmacy and co-morbidity- risks and benefits must be balanced for each 
patient.  
A troubling fact is that elderly patients with major cardiovascular diseases are 
denied from indicated medical treatments probably due to chronological age 
alone.36 But, temporal trend analysis of prescribing patterns have shown 
improvements in prescribing evidence-based therapies to the elderly. In a study 
of very old patients (> 85 years), between 2003 and 2010 the rates of 
prescription of the following secondary prevention medications increased: 
clopidogrel (28-89%), statins (61-69%) and beta-blockers (49-56%).23  
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In another large study, medical therapy among the elderly with ACS increased 
with time (1998-2010), and with increasing age there was an increase in 
therapy until age 75 (statins) and 85 (anti-hypertensive therapy), then an age 
related decline in therapy rates occured.37 
Antithrombotic therapy or antiplatelet therapy is essential to modify the disease 
process in coronary disease. The oral antiplatelets used today are aspirin and 
the thienopyridines or P2Y12 antagonists. The intensity of treatment is based on 
individual risk.  
Aspirin  
Aspirin (ASA) irreversibly inhibits cyclooxygenase-1 within platelets and thus 
prevents the formation of thromboxane A2. As a result, platelet aggregation 
diminishes promoted by this pathway.  
Aspirin is recommended for all elderly patients, in the absence of 
contraindications, without any dosage adjustment in the elderly. A meta-
analysis has shown the benefit in high-risk groups, such as the elderly, to 
exceed the hazard.38 Nevertheless, there exists a problem of aspirin 
undertreatment in elderly individuals.39 
Thienopyridines  
The P2Y12 receptor is the main platelet receptor responsible for adenosine 
diphosphate–induced platelet aggregation.   P2Y12 inhibitors common (in the 
past and present) in clinical use are: ticlopidine, prasugrel, clopidogrel, and 
ticagrelor.  
Due to safety reasons, the first generation thienopyridine ticlopidine has been 
replaced with other drugs. 
In the TRITON–TIMI 38 trial,40 the potent P2Y12 inhibitor prasugrel was 
associated with a reduction in ischemic events compared with clopidogrel in 
high-risk ACS patients undergoing PCI. Post-hoc analysis identified patients at 
higher risk in whom prasugrel was associated with harm, with no net clinical 
benefit as the ischemic benefit was offset by the risk of bleeding, including the 
elderly (age >75 years). Due to these findings, the use of prasugrel in patients 
>75 years of age is generally not recommended. 
In the substudy of a randomized trial (PLATO) comparing two different age 
strata (younger or older than 75years),41 the clinical benefit and overall safety 
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of ticagrelor compared with clopidogrel in ACS patients were not found to 
depend on age. 
In this regard, the medications most commonly used today are ticagrelor and 
clopidogrel. Clopidogrel is more widely used in the cohort concomitantly 
treated with Vitamin K-antagonists (warfarin). 
Beta-blockers 
Beta-blockers competitively block the effects of catecholamine on cell 
membrane beta-receptors. By doing so, they decrease the contractility and heart 
rate responses to chest pain, exertion and other stimuli. They also decrease 
blood pressure.  
After myocardial infarction, patients with conditions that are often considered 
to be contraindications for beta-blockade, such as pulmonary disease and older 
age, benefit from beta-blocker therapy.42,43 
In the elderly without contraindications, due to safety reasons, a reasonable 
approach would be to start with low dose of beta-blocker and titrate slowly 
especially in those with conduction abnormalities, peripheral artery disease or 
obstructive lung disease. 
ACE-I 
Angiotensin-Converting Enzyme Inhibitors (ACE-I) inhibit one step in the 
renin-angiotensin pathway. ACE-I has been shown to reduce mortality rates in 
patients with myocardial infarction. 
Even though there is benefit of treatment with ACE-I, particularly in patients 
with reduced left ventricular function, the side effects of ACE-I treatment may 
outweigh benefit in elderly patients. The American Geriatric Society has 
published a list of medications that are potentially inappropriate for older adults 
(also known as the Beers criteria).44 ACE-I is included on this list due to risk 
for orthostatic hypotension and syncope. Other examples of common 
medications that may be inappropriate for older adults, mentioned in the Beers 
criteria, are: Digoxin, Spironolactone, Prasugrel and NSAIDs. 
Due to the risk for adverse effects, ACE-I should be tested in low dose among 
elderly ACS patients without contraindications to therapy, and titrated carefully 
with monitoring of renal function, potassium and blood pressure. 
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Statins 
Statins have been shown to beneficial in prevention of subsequent MI and 
death, primarily by lipid-lowering effects. Hyperlipidemia is a significantly 
modifiable risk factor for coronary heart disease, but approaches to such 
modification must be considered in light of the individual´s life expectancy and 
risk for side effects.  
In the ACC/AHA Lipid guidelines45 high-intensity statins, such as Atorvastatin 
80 mg, has been recommended for patients below 75 years of age, but in those 
above 75 years moderate intensity statins are recommended instead. These 
recommendations have been based on low evidence for benefit and higher risk 
with high-intensity statins based on age. In contrast, the European guidelines46 
state a universal statin treatment regimen without any treatment modification in 
regards to age. 
Statin-associated muscle effects (SAME) is an umbrella term for muscle related 
symptoms in patients on statin drugs, such as: myopathy, rhabdomyolysis and 
myalgia. Even in the absence of statin therapy, the elderly often have 
complaints of pain from the musculoskeletal system, so determining if the 
complaint is an adverse drug effect may be challenging. Even though some 
patients with SAME require drug discontinuation, many patients can tolerate a 
switch to a different statin or lower dose. 
Cognitive dysfunction has been recognized as an adverse effect of statins, based 
on cases reported in the FDA´s Adverse Event Reporting System.47 This serious 
side effect would be especially important in the elderly, based on the higher 
prevalence of dementia with increasing age - one reason why statin therapy 
may be withheld. Observational studies have reported reversibility of the 
cognitive changes after a few weeks of discontinuation of the drug.48 
When treating older adults, care must be given to life expectancy and the time 
to perceived benefit of the intervention or drug therapy. Regarding statins, the 
time to see full benefit from statins can be 2-3 years49 but is has been shown to 
be shorter among those on a statin for secondary prevention. 
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CONSERVATIVE OR INVASIVE TREATMENT  
Initial therapy for ACS should focus on stabilizing the patient´s condition. In 
addition, relieving chest pain, providing antithrombotic therapy, and 
revascularization when appropriate to reduce myocardial damage. Medical 
treatment would commonly include a low-molecular-weight heparin (LMWH) 
in addition to the aforementioned therapy, if no contraindications exist.  
Invasive treatment (coronary angiography and intervention if feasible) of 
patients with (ACS) has been shown to lead to better outcomes than medical 
therapy alone,35 but the elderly have been under-represented in many of the 
studies. The benefit and risk of ACS treatment is discussed in more detail in a 
later chapter. 
Selection of treatment method in the elderly (Paper II) 
In order to describe the differences between elderly MI patients who are 
selected for conservative or invasive therapy, one must have a database that 
includes all patients regardless of the admitting department in hospital. In Paper 
II, elderly patients admitted to all departments in a Swedish hospital were 
included, for example those who were admitted to a surgical department and 
had a periprocedural MI. 
There are limited data on very elderly patients with MI especially those 
conservatively treated. Conservatively treated patients often get excluded from 
studies, even observational studies, due to the fact that study design includes 
only those admitted to specialized cardiology departments or those undergoing 
an intervention.  
The aim of Paper II50 was to explore differences between elderly MI patients 
selected for invasive or conservative treatment strategy. The characteristics 
describing the group of conservatively treated patients were of high interest. 
The clinical characteristics and outcome was compared in 1413 elderly patients 
(>75 years old) admitted to Sahlgrenska University Hospital (Gothenburg, 
Sweden) with a final diagnosis of acute myocardial infarction in 2001 and 
2007. The group was stratified into patients receiving a conservative treatment 
strategy (conservative group=CG) and those patients who underwent coronary 
angiography and were revascularized if indicated (invasive group=IG). The 
decision whether to treat the patient with the invasive treatment strategy or not 
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was made by the treating physicians, who were not aware of this study 
(retrospective data collection).  
The results of Paper II is that other than higher age in the CG, traditional risk 
factors like hypertension, diabetes and smoking did not turn out to differ 
between those in the CG and IG. Heart failure, both as previous history and at 
presentation, and cerebrovascular disease turned out to be higher in the CG. 
Table 2 shows the characteristics of elderly patients with MI at presentation to 
hospital. 
 
Table 2. Characteristics of elderly patients with MI, at presentation (%) 
 
Overall, among the elderly with MI the proportion undergoing an invasive 
treatment strategy doubled from 12% in year 2001 to 24% in year 2007, despite 
a slightly higher mean age. 
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factors such as hypertension, diabetes, and smoking were not 
significantly different in the IG and the CG (Table 1).
Patients who were treated at a hospital with PCI facilities 
had a higher proportion of elderly patients who underwent a 
coronary angiogram, 21% versus (vs) 13%, P?0.003.
Only one patient was lost to follow-up (at 355 days), due 
to emigration. Two patients (one in 2001 and one in 2007) 
underwent an in-hospital CABG but had coronary angiogra-
phy performed before hospitalization, therefore meeting the 
criteria for inclusion in the CG. The difference between the 
IG and CG regarding prior atrial fibrillation was significantly 
smaller in 2007 than in 2001 (P?0.003 for time period by 
treatment interaction).
Factors deﬁning the CG
The patients in the CG were generally older, had more co-
morbid disorders, and had poorer outcome than those in the 
IG. More patients in the CG had previous congestive heart 
failure and cerebrovascular disease than the patients in the 
IG. There were no significant differences regarding the other 
co-morbidities studied (cancer, renal disease, and connective 
tissue disease). Previous history of congestive heart failure 
was more than three times higher in the CG than in the IG 
(41% vs 13%, P?0.0001).
Also, a lower percentage of patients in the CG ha  typi-
cal symptoms and sign  of MI, such as chest pain (76% vs 
93%, P?0.0001) and ECG with ST-elevation indicating 
myocardial ischemia (8% vs 26%, P?0.0001), as shown 
in Table 2.
Treatment was shifting towards PCI
A higher proportion of elderly patients were treated with PCI 
in 2007 than in 2001, and thrombolytic therapy was almost 
non-existent in 2007.
Outcome
In-hospital death and events such as pneumonia and con-
gestive heart failure were more common in the CG than in 
the IG (Table 3). More than one third of the patients in the 
CG had congestive heart failure during hospitalization but 
the corresponding proportion for the IG was less than one 
fifth (P?0.0001). The unadjusted Kaplan–Meier survival 
estimates in the IG and CG for each time period are shown 
in Figure 1. When we adjusted for potential confounders, 
as described in Statistical methods, there was a significant 
difference regarding 5 year mortality in favor of the IG 
(hazard ratio 0.49, 95% confidence interval 0.39–0.62, 
P?0.0001).
Discussion
In this study of elderly patients ospitalized for MI, we found 
differences in previous history, presentat n, in-hospital 
Table 2 Presentation (%)
2001 2007 2001?2007 P* P**
Cons  
(n?706)
Inv  
(n?97)
Cons  
(n?463)
Inv  
(n?147) 
Cons  
(n?1,169)
Inv  
(n?244)
Symptoms
Chest pain/pressure/discomfort 81a 98 68a 90 76a 93 ?0.0001 0.18
Loss of consciousness 7a 5 9 5 8a 5 0.13 0.79
Pulmonary edema or cardiogenic 7 5 10 8 8 7 0.24 0.81
shock
Other at presentation
Cardiogenic shock 1a 0 ?1a 3 1a 2 0.27 0.15
Congestive heart failure 45 15 52a 27a 48a 22a ?0.0001 0.28
ECG recording available# 46 77 85 84 61 82 ?0.0001 0.0001
ST elevation 9 23 7 28 8 26 ?0.0001 0.15
Location
Anterior 8 20 6 19 7 19 ?0.0001 0.55
Inferior 2 9 2 15 2 13 ?0.0001 0.26
Lateral 0 3 0 2 0 3 0.0005 1.00
ST-depression 27 31 25 35 26 33 0.008 0.45
LBBB 15 8 15 8 15 8 0.005 0.96
Other pathological ECG changes 50 59 44 49 46 53 0.09 0.74
Normal ECG 23 20 27 19 25 20 0.10 0.54
Sinus rhythm 67 81 68 76 68 78 0.07 0.45
Notes: *For difference between conservative and invasive treatment strategy groups (age adjusted); **for time period by treatment interaction; #percentages below refer to 
patients with available ECG recordings; a1%–5% missing.
Abbreviations: Cons, conservative; Inv, invasive; ECG, electrocardiogram; LBBB, left bundle branch block.
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Figure 6. Kaplan-Meier curve describing survival in elderly patients with MI related to year and 
treatment strategy group. 
 
The conclusions of Paper II are that elderly patients with MI in the conservative 
treatment strategy group are older and have more chronic diseases, such as 
congestive heart failure and cerebrovascular disease. Although it is tempting to 
attribute the apparently lower mortality rate to the invasive treatment strategy, 
as shown in figure 6, a causative assumption cannot be made due to risk for 
bias (confounding by indication). Such a conclusion must be confirmed by a 
randomized clinical trial. One randomized trial has been started in Sweden and 
is still recruiting (Paper IV); this trial is designed to evaluate the treatment 
effect of conservative and invasive treatment strategy in the elderly with ACS. 
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events, and outcome between patients in the conservative 
treatment strategy group and those in the invasive treatment 
strategy group.
The invasive treatment strategy is on the 
increase
Even though the proportion of patients in the IG doubled 
between 2001 and 2007, we believe that 24% is still a low 
percentage. A study from 2008 showed that elderly patients 
were less likely to undergo PCI than younger cohorts, and 
among the oldest (?80 years old), 20% underwent PCI for 
NSTEMI and 30% for STEMI, which is in line with our 
results.9 More recent studies have also shown increasing PCI 
in the elderly, especially in STEMI patients.10,11 This could 
be due to increased availability of PCI, to physicians not dis-
criminating against patients based on age and becoming more 
comfortable about performing procedures on the elderly, to 
the aging population in general, and to emerging evidence in 
favor of PCI.12,13 Still, practical risk-scoring systems should 
be developed to help clinicians and patients better understand 
the risks and benefits associated with the invasive treatment 
strategy in elderly people with MI.
Heart failure
Heart failure and cerebrovascular disease were common in 
elderly people who were not referred for a coronary angiog-
raphy, which is in line with another observational study.14 
One possible explanation would be that heart failure patients 
have higher levels of cardiac enzymes, especially elderly 
patients, and they more often have baseline ECG changes, 
making the diagnosis of MI more difficult. Another factor 
that could play an important role is uncertain benefit from 
Table 3 In-hospital procedures and events (%)
2001 2007 2001?2007 P* P**
Cons  
(n?706)
Inv  
(n?97) 
Cons  
(n?463)
Inv  
(n?147) 
Cons  
(n?1,169)
Inv  
(n?244)
Thrombolysis 4 16 ?1 0 3 7 0.04 0.18
Procedures and treatment
Echocardiography 31 82 25 70 29 75 ?0.0001 0.29
Exercise bicycle test 6 20a 2 2a 4 9a 0.61 0.08
PCI 0 42 0 75 0 62 – –
Primary 0 33a 0 65 0 52 – –
Rescue 0 7a 0 0 0 3 – –
Elective 0 1a 0 10 0 6 – –
CABG ?1 27 ?1 7 ?1 15 ?0.0001 0.21
Events
Recurrent AMI 3 6 2 4 2 5 0.01 0.94
Pulmonary embolism ?1a 0 2 0 1 0 0.07 1.00
Pneumonia 12a 6 9 1 10a 3 0.0005 0.13
Stroke 6a 4 3 ?1 5 2 0.11 0.22
Deep vein thrombosis ?1a 1 ?1 0 ?1 ?1 1.00 0.75
Acute renal failure 4a 1 2 ?1 4 ?1 0.055 0.91
Hemorrhage requiring transfusion 4a 0 6 1 5 ?1 0.01 0.22
Hypotension 14a 5 16 18 15 13 0.35 0.02
Pericarditis 0a 1 0 ?1 0 ?1 0.046 1.00
Cardiogenic shock 3a 3 2 3 2 3 0.87 0.50
Congestive heart failure 54 29 19 13 40 19 ?0.0001 0.11
Death 20 6 20 10 20 9 0.0003 0.31
Notes: *For difference between conservative and invasive treated groups (age adjusted); **for time period by treatment interaction; a1%–5% missing.
Abbreviations: Cons, conservative; Inv, invasive; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; AMI, acute myocardial infarction.
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Figure 1 aplan- eier curve describing survival in elderly patients with MI related 
to treatment strategy group.
Abbreviation: MI, myocardial infarction.
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UNTANGLING CLINICAL COMPLEXITY 
"For every complex problem there is an answer that is clear, simple, and 
wrong." 
-H.N. Mencken 
 
There must be done a careful weighing up of benefit and risk in the elderly 
population. But, as explained in this chapter, this task might turn out to be 
challenging. In addition, the life quality and life expectancy of the individual 
should be taken into consideration. These factors, risk, benefit, quality of life 
and life expectancy should be the base for a discussion with the patient and 
their family regarding treatment strategy.  
Figure 7. Factors that should be taken into consideration during clinical decision making, in 
complex elderly patients. Illustration by the author 
In patients with high risk for complications and in some cases unclear benefit 
from active treatment - a shared decision making with the patient, medical 
caregivers and family would be the most reasonable approach. Having 
conversations about the goal of care earlier in the course of illness often affects 
satisfaction and choices patients make. A patient-doctor relationship with 
continuity is the ideal context for a stepwise approach to discussing the goals of 
care. But unfortunately, in the era of the escalating productivity requirements 
currently characterizing medical practice many physicians may feel that they 
!
Prognosis! •  Evaluate!life!expectancy!!
Risk! •  Evaluate!risks!
Bene9it! •  Evaluate!bene9it!
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lack time to manage complex symptoms, emotional, practical and social needs 
in their patients. Also, physicians may feel lack of competence and training 
dealing with complex situations and as a consequence, a tempting approach 
may be simply treating the disease within the field of expertise- instead of 
tackling complexity. 
Dealing with patients with emptied treatment options, or unfixable problems, 
can be a difficult situation for caregivers. Doctors are taught to fight disease, 
and shifting treatment goal from curative to palliative care can be regarded as 
abandoning the patient and taking away patients' hope. Interestingly, a 
randomized study of cancer patients showed the opposite, that palliative care 
increased survival, quality of life and mood compared to standard care.51 
Moreover, there may exist unclear responsibility to who should initiate end-of-
life decisions: The primary care physician, geriatric specialist at the nursing 
home, nursing staff or the hospital specialist treating the patient during acute 
illness?  
Prognosis and life expectancy  
To better target services to those who may benefit from treatment, many 
guidelines recommend incorporating life expectancy into clinical decisions. 
This may be a difficult task, prone to subjectivity, but many prognostic indices 
have been described in order to guide clinicians. The quality of these have been 
evaluated in a systematic review52 and some are available online, such as 
ePrognosis (http://eprognosis.ucsf.edu). They are designed to complement, not 
replace, the relationship between a patient and the medical provider. The 
clinician can estimate the patient’s mortality by answering a series of questions 
included in each index. The risk score is correlated with an absolute risk of 
mortality for a specified time period. One must though add clinical judgment to 
decide if the estimated mortality risk seems reasonable. Prognostic indices offer 
a potential role for moving beyond age-based cutoffs in clinical decision-
making. 
In order to define patients who need different treatment than guidelines 
advocate due to complexity and risk, methods have been evolved in order to 
define the minimum elapsed time until the cumulative incremental benefits of a 
guideline exceeds its cumulative incremental harm, such as the payoff model.53 
If the payoff time of a guideline exceeds a patient's comorbidity-adjusted life 
expectancy, then the guideline is unlikely to benefit the patient and should be 
modified. Whether or not this approach helps patients is unclear, but it can be 
regarded as an additional tool in the assessment of the patient. 
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EVALUATING RISK IN THE ELDERLY  
 
 
 
 
 
 
 
 
 
Figure 8. Risk in the elderly may be due to different factors; all contribute to the total individual 
risk. Illustration by the author 
 
Overtreating the elderly may do more harm than benefit due to adverse events. 
When treatments are more complex and risky, it gets more important to know 
the patients risk factors for bad outcome. The accurate risk stratification of 
older adults would allow targeting of medications and interventions to those 
who benefit from treatment without taking unnecessary risk.  
Even though time-consuming, a comprehensive assessment of the older person 
to address individual problems that may compromise the safety and 
effectiveness of treatment is necessary. The elements of this assessment would 
be: function, co-morbid diseases, cognition and psychological conditions, 
socioeconomic conditions, medications, nutrition and finally, geriatric 
syndromes, such as frailty.  
In general, there are four different types of risk for bad outcome that can occur 
simultaneously in the same individual. Firstly, age-related risk, secondly 
competing risk, thirdly disease related risk and finally, treatment related risk 
(figure 8). 
!
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Age related risk 
Chronological age is a strong independent factor increasing risk for mortality in 
acute coronary syndrome,54 even after adjusting for differences in baseline risk 
(competing risk) and therapeutic differences. Obviously, chronological age is a 
non-modifiable risk factor.  
As previously mentioned, organ reserve capacity decreases with age. Due to 
physiological changes, age is usually found to be an independent predictor for 
bad outcome, such as increased mortality and morbidity. Chronological age is a 
variable in some of the popular risk calculators in cardiology, such as the 
Framingham risk score55 and the GRACE risk score.56 
 
Competing risk 
Comorbid diseases are other diseases the patient has simultaneously to one 
condition. The risk for adverse events (morbidity and mortality) increases with 
comorbid diseases and therefore in research and in the clinical setting this is 
sometimes described as competing risk. 
The causes of two or more diseases co-existing can be: genetic (mutation of a 
gene causing 2 different diseases), single pathogenic mechanism causing a 
number of diseases, anatomic proximity of diseased organs, cause-effect 
relation between diseases, one disease resulting from complications of another 
or of course simply by chance. 
In average, elderly patients have multiple disorders.57 A disorder in one organ 
system can weaken another, leading to deterioration of both with risk for 
disability, dependence and mortality. In patients with many comorbid diseases, 
treatments must be well integrated. Treating one disorder without taking into 
consideration co-morbidity may lead to clinical detoriation.  
In order to capture the value of comorbid conditions, there have been evolved 
tests or indices to consolidate each individual comorbid condition into a single, 
predictive variable that measures outcome, such as mortality. No one test is as 
yet recognized as a standard but experts have validated such tests because of 
their predictive value. In research, such indices have been used to adjust for 
heterogeneity in study groups, in order to decrease bias. 
One more popular index used today to capture the increased risk of co-
morbidity is the Charlson index58 but many other indices do exist.59 After 
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adding the points in the Charlson comorbidity index (table 3) both from the 
comorbidity score and age score, one can calculate the estimated 10-year 
mortality risk by using a mathematical formula. 
 
Score Condition 
1 point 
for each 
Myocardial infarction (history, not ECG changes only), 
congestive heart failure, Peripheral vascular disease, 
cerebrovascular disease, dementia, chronic pulmonary disease, 
connective tissue disease, peptic ulcer disease, mild liver disease, 
diabetes without end-organ damage (excludes diet-controlled 
alone)  
2 points 
for each 
Hemiplegia, moderate or severe renal disease, diabetes with end-
organ damage, tumor without metastasis (exclude if > 5years from 
diagnosis), Leukemia (acute or chronic), Lymphoma 
3 points 
for each 
Moderate or severe liver disease 
6 points 
for each  
Metastatic solid tumor, AIDS (not just HIV positive) 
 
Table 3. The Charlson comorbidity index. For age >40 years, for each decade 1 point 
is added.  
 
Although helpful, the different indexes are far from perfect. No single generally 
accepted method exists. When using different international comorbidity 
assessment scales, a clinician would come across totally different evaluations 
due to their inconsistency. The uncertainty of the result might complicate the 
doctor’s judgment about the level of severity of the patient’s condition. These 
tools are proven to be helpful in research of elderly patients, due to the high risk 
of competing risks and therefore bias. One example would be using the 
Charlson comorbidity index in the statistical analysis, in order to adjust for 
comorbidity. 
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The current paradigm of care for the elderly is based on extrapolation from 
conventional evidence-based guidelines for each of the multiple diseases these 
patients often suffer. However, there is no evidence that the evidence-based 
therapeutic approach to a single disease is also applicable to multiple diseases 
and the corresponding use of multiple medications, due to non-existing studies 
of polypharmacy in patients with multiple diseases. Not only is evidence-based 
knowledge on the efficacy of polypharmacy lacking but also there is no 
information about the safety of polypharmacy. 
Subspecialists sometimes find it difficult to tackle all the different diseases, 
which are unlikely to be seen concomitantly in the younger patients they are 
more accustomed to caring for. 
Among some ACS patients the balance of co-morbidity may be such that 
revascularization may not offer an acceptable level of periprocedural risk. 
Disease related risk 
When diagnosed with a disease the patient will have increased risk for mortality 
or morbidity associated with his/her new diagnosis. In the population of ACS 
patients, examples of patients with high risk for death would be those 
presenting after cardiac arrest, with cardiogenic shock or STEMI.  
Age is a prognostic marker in the majority of the ACS risk scores, negatively 
effecting survival. There has been observed an inverse relationship between the 
rate of PCI (or the rate of angiography) and risk status (myocardial infarction or 
mortality) of the patient60 indicating that referral to PCI is more likely to be 
based on referral practice or angiographic findings- rather than validated risk 
scores. Even though this finding is disturbing, as guidelines advocate 
revascularization in patients with moderate or high risk for mortality- 
unacceptable procedural risk might be the reason for procedures being 
withheld. 
Treatment related risk  
Among the elderly, there is risk associated with both medical treatment and 
invasive procedures. Interventions can have life-altering effects extending 
beyond that of the original diagnosis for which the intervention was indicated.  
In particular elderly patients with lower homeostatic threshold the stress 
associated with surgery can lead to imbalance in autonomic, endocrine, 
metabolic, and immune factors.  
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The significance of activation of the autonomic sympathetic response, related to 
surgery, could have negative effects in elders due to hypertension, tachycardia 
and possibly arrhythmias. The net effect can result in increased oxygen 
demand, which can add to ischemia in vulnerable patients with preexisting 
coronary heart disease. In addition, circulating catecholamines may contribute 
to a hypercoagulable state and trigger coronary vasoconstriction- all factors that 
can add to risk for myocardial ischemia associated with treatment. 
There exist many potential problem domains with prescribing drugs to the 
elderly. The high prevalence of polypharmacy with aging may lead to an 
increased risk of inappropriate drug use, underuse of effective treatments, 
medication errors, poor adherence, drug–disease and drug–drug interactions 
and, most importantly, adverse drug reactions.  
Toxicity of medical therapy is a problem with higher prevalence among the 
elderly. This is due to impairment of homeostatic mechanisms (such as delayed 
gastric emptying, less intestinal motility, decrease in lean body mass and lower 
serum albumin), increase of co-existing diseases (such as renal and liver 
failure), and the fact that older patients are often taking several medications 
concurrently. When prescribing for the elderly these factors should be kept in 
mind, in order to minimize the risk for unwanted effects. In many cases the 
dose should be reduced or the dose interval increased. One problem is that 
randomized trials, that provide the base for medical therapy, include few 
elderly study individuals, so the safety of drugs tends to be overrated. 
Clinicians should be aware of these problems and review drugs frequently in 
elderly individuals in order to avoid adverse events. 
In a systematic review61 examining the adverse drug reactions (ADR) among 
hospitalized elderly, one in ten elderly patients will experience an ADR leading 
to, or during their hospitalization. Older female patients and those with multiple 
comorbidities and multiple medications were more likely to experience an 
ADR. 
In the elderly with coronary disease, there exists higher risk for bleeding but 
also a higher risk for ischemia and hence, higher presumed benefit from 
treatment with antithrombotic therapy- which can make treatment choice 
difficult.  
Age is a predictor for greater rate of all PCI-related complications.62 Bleeding 
after PCI has been associated with increased mortality and the reasons can be 
multiple. Firstly, cessation of evidence-based therapy such as antithrombotic 
therapy, secondly, anemia itself that may drive myocardial ischemia, thirdly, 
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unwanted effects of blood products transfused and finally, greater prevalence of 
co-morbidities in those who bleed. In addition, making things even more 
complicated: With increasing age the prevalence of atrial fibrillation (AF) 
increases and the risk for stroke. Accordingly, there will be a higher rate of 
elderly patients on anti-coagulant drugs further adding to the risk for bleeding 
associated with anti-platelet drugs or PCI. The use of verified risk assessment 
scores for bleeding, such as CRUSADE,63 which does not include age, may 
enable more objective assessment to evaluate bleeding risk. 
 The group of patients over 80 years of age that experience periprocedural 
complications are at particular risk.64 
Due to the aforementioned therapy related risk, interventions, such as PCI for 
ACS should be kept as simple, swift and safe as possible. 
 
Risk related to therapy in STEMI patients (Paper III) 
In order to evaluate risk related to therapy in a population of patients, one 
would need a database that captures hopefully all patients undergoing the 
procedure, during a defined time period. In Paper III,65 the Swedish Coronary 
Angiography and Angioplasty Registry (SCAAR) was used to study elderly 
patients undergoing PCI for STEMI.  
The SCAAR registry is a population-based quality registry in Sweden, 
sponsored by the Swedish Health Authorities. All consecutive coronary 
angiographies and PCI procedures performed in Sweden are documented. In 
total 30 hospitals with a catheterization laboratory enroll patients. Only during 
the first years, a few PCI procedures may have been performed outside of the 
SCAAR registry. The data are collected prospectively. During the over 20 years 
the registry has existed, temporal trends show that the mean age of patients has 
increased, PCI indication has shifted to be more frequently ACS instead of 
stable coronary disease and the complexity of the coronary pathology has 
increased with more multivessel and left main disease being treated with PCI.66 
In Paper III, consecutive patients with STEMI, 80 years or older undergoing 
primary PCI during a 10-year period (2001-2010) were identified. Temporal 
trends in care and outcome were investigated, and long-term outcome was 
compared with a reference group of patients with STEMI aged 70 to 79 years.  
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Table 4. Baseline characteristics of elderly patients, treated with primary PCI  
 
Table 5. Angiographic and procedural characteristics of elderly patients treated with 
primary PCI for STEMI 
 
In total, 4,876 elderly patients with STEMI were included. As shown in table 4 
and 5, during the study period, average age and presence of comorbidity 
increased, as well as the use of antithrombotic therapy. The percentage of 
patients over 90 years old increased during the study period (2,8 % - 6,9 %). 
Procedural success remained constant. One-year mortality was exclusively 
reduced between the most recent vs. the earliest cohort, whereas the risk of 
reinfarction, heart failure, stroke, and bleeding remained similar. The risk of 
age and the proportion of patients of very advanced age
increased (Table I). The ratio of male to female patients
remained the same during the study period. Hypertension,
hyperlipidemia, prior coronary artery bypass grafting, and a
history of kidney failure were more common over time,
whereas the percentage of patients with prior myocardial
infarctions declined. A reduction in time from symptom
onset to PCI was observed between the earliest and the
later cohorts. In addition, presence of cardiogenic shock
decreased over time.
Procedural characteristics showed a pronounced
increase in the use of the radial approach during PCI
(Table II). The total rate of stenting was stable over
time, although stent type varied. Procedural success was
similar over the years and was more than 90% for all
cohorts. The overall use of antithrombotic therapy
Table I. Baseline characteristics
2001-2004
(n = 814)
2005-2006
(n = 1222)
2007-2008
(n = 1427)
2009-2010
(n = 1413)
P for
trend
Age (y), mean ± SD 83.1 ± 2.7 83.7 ± 3.1 84.0 ± 3.2 84.0 ± 3.3 b.001
Age ≥90 y 23 (2.8) 61 (5.0) 92 (6.4) 98 (6.9) b.001
Male gender 449 (55.2) 641 (52.5) 720 (50.5) 716 (50.7) .130
Diabetes mellitus 114 (14.3) 170 (13.9) 187 (13.1) 205 (14.5) .813
Hypertension 291 (36.1) 514 (42.1) 628 (44.0) 746 (52.8) b.001
Hyperlipidemia 91 (11.7) 138 (11.3) 192 (13.5) 243 (17.2) b.001
Current smoker 53 (6.6) 76 (6.2) 94 (6.6) 102 (7.2) .775
History of
Myocardial infarction 189 (23.4) 222 (18.2) 190 (13.3) 189 (13.4) b.001
Coronary artery bypass grafting 17 (2.1) 28 (2.3) 37 (2.6) 41 (2.9) .010
Peripheral vascular disease 38 (4.7) 51 (4.2) 53 (3.7) 60 (4.2) .737
Stroke 99 (12.2) 182 (14.9) 184 (12.9) 180 (12.7) .241
Kidney failure 9 (1.1) 17 (1.4) 29 (2.0) 42 (3.0) .006
Cancer in the last 3 y 31 (3.8) 45 (3.7) 47 (3.3) 70 (5.0) .131
Onset symptoms to PCI (min), median (IQR) 317 (169-865) 255 (163-485) 230 (148-451) 235 (145-450) .003
First ECG to PCI (min), median (IQR) 82 (37-173) 84 (50-148) 77 (49-131) 78 (50-120) .074
Cardiogenic shock 65 (9.7) 87 (7.3) 106 (7.4) 64 (4.5) b.001
Follow-up duration (y), median (IQR) 7.1 (6.4-8.2) 4.9 (4.4-5.4) 2.9 (2.5-3.4) 1.0 (0.5-1.5) –
Abbreviation: ECG, Electrocardiogram.
Table II. Angiographic and procedural characteristics
2001-2004
(n = 814)
2005-2006
(n = 1222)
2007-2008
(n = 1427)
2009-2010
(n = 1413) P for trend
Vascular access b.001
Femoral access 610 (94.3) 1056 (86.4) 1103 (77.3) 820 (58.1)
Radial access 37 (5.7) 163 (13.3) 320 (22.4) 588 (41.6)
Angiographic findings b.001
Single-vessel disease 274 (37.4) 393 (32.8) 533 (37.4) 512 (36.3)
Dual-vessel disease 192 (26.2) 346 (28.9) 403 (28.2) 405 (28.7)
Triple-vessel disease 185 (25.2) 341 (28.4) 369 (25.9) 343 (24.3)
Left main disease 80 (10.9) 109 (9.1) 104 (7.3) 114 (8.1)
Treatment technique b.001
Only balloon angioplasty 80 (9.9) 116 (9.5) 175 (12.3) 169 (12.0)
Bare-metal stenting 650 (80.0) 816 (66.7) 1175 (82.5) 1106 (78.4)
Drug-eluting stenting 82 (10.1) 290 (23.8) 74 (5.2) 135 (9.6)
Stent length (mm), mean ± SD 17.1 ± 6.1 18.0 ± 6.2 17.6 ± 5.8 17.8 ± 5.8 .003
Stent diameter (mm), mean ± SD 3.1 ± 0.5 3.0 ± 0.5 3.0 ± 0.5 3.0 ± 0.5 .041
Procedural success 725 (92.6) 1110 (91.0) 1303 (91.5) 1287 (91.4) .651
Medication
Any antithrombotic treatment prior to PCI 505 (62.7) 1054 (87.5) 1227 (86.2) 1235 (87.7) b.001
Aspirin before PCI 482 (59.4) 1015 (83.2) 1152 (80.9) 1167 (82.9) b.001
P2Y12 inhibitor before PCI 192 (23.8) 636 (52.3) 956 (67.1) 1030 (73.2) b.001
Thrombolysis prior to PCI 95 (11.8) 43 (3.6) 17 (1.2) 17 (1.2) b.001
Glycoprotein IIb/IIIa inhibitor during PCI 400 (49.3) 657 (53.8) 570 (40.0) 334 (23.7) b.001
Bivalirudin during PCI – 166 (15.7) 485 (34.1) 779 (55.3) b.001
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age and the proporti n of patients of very advanced age
increased (Table I). The ratio of male to female patients
remain the same during the study p ri d. Hyp rtension,
hyperlipidemia, prior coronary artery bypass grafting, and a
history of kidney failure were more common over time,
whereas the p rcentag of patients with pri r myocardial
infarctions declined. A reductio in time fr m symptom
onset to PCI was observe between the earliest and the
later cohorts. In addition, presence of cardiogenic shock
decreased over time.
Procedural characteristics showed a pronounced
increas in the use of the radial approach during PCI
(Table II). The total rate of stenting was stable over
time, although stent type varied. Procedural success was
si ilar over t e years and was more than 90% for all
cohorts. The overall use of antithro botic therapy
Table I. Baseline characteristics
2001-2004
(n = 814)
2005-2006
(n = 1222)
2007-2008
(n = 1427)
2009-2010
(n = 1413)
P for
trend
Age (y), mean ± SD 83.1 ± 2.7 83.7 ± 3.1 84.0 ± 3.2 84.0 ± 3.3 b.001
Age ≥90 y 23 (2.8) 61 (5.0) 92 (6.4) 98 (6.9) b.001
Male gender 449 (55.2) 641 (52.5) 720 (50.5) 716 (50.7) .130
Diabetes mellitus 114 (14.3) 170 (13.9) 187 (13.1) 205 (14.5) .813
Hypertension 291 (36.1) 514 (42.1) 628 (44.0) 746 (52.8) b.001
Hyperlipidemia 91 (11.7) 138 (11.3) 192 (13.5) 243 (17.2) b.001
Current smoker 53 (6.6) 76 (6.2) 94 (6.6) 102 (7.2) .775
History of
Myocardial infarction 189 (23.4) 222 (18.2) 190 (13.3) 189 (13.4) b.001
Coronary artery bypass grafting 17 (2.1) 28 (2.3) 37 (2.6) 41 (2.9) .010
Peripheral vascular disease 38 (4.7) 51 (4.2) 53 (3.7) 60 (4.2) .737
Stroke 99 (12.2) 182 (14.9) 184 (12.9) 180 (12.7) .241
Kidney failure 9 (1.1) 17 (1.4) 29 (2.0) 42 (3.0) .006
Cancer in the last 3 y 31 (3.8) 45 (3.7) 47 (3.3) 70 (5.0) .131
Onset symptoms to PCI (min), median (IQR) 317 (169-865) 255 (163-485) 230 (148-451) 235 (145-450) .003
First ECG to PCI (min), median (IQR) 82 (37-173) 84 (50-148) 77 (49-131) 78 (50-120) .074
Cardiogenic shock 65 (9.7) 87 (7.3) 106 (7.4) 64 (4.5) b.001
Follow-up duration (y), median (IQR) 7.1 (6.4-8.2) 4.9 (4.4-5.4) 2.9 (2.5-3.4) 1.0 (0.5-1.5) –
Abbreviation: ECG, Electrocardiogram.
Table II. Angiographic and procedural characteristics
2001-2004
(n = 814)
2005-2006
(n = 1 22)
2007-2008
(n = 1427)
2009-2010
(n = 1413) P for trend
Vascular access b.001
Femoral access 610 (94.3) 1056 (86.4) 1103 (77.3) 820 (58.1)
Radial access 37 (5.7) 163 (13.3) 320 (22.4) 588 (41.6)
Angiographic findings b.001
Single-vessel disease 274 (37.4) 393 (32.8) 533 (37.4) 512 (36.3)
Dual-vessel disease 192 (26.2) 346 (28.9) 403 (28.2) 405 (28.7)
Triple-vessel disease 85 ( 5. ) 341 (28.4) 369 (25.9) 3 3 (24.3)
Left main disease 80 (10.9) 109 (9.1) 104 (7.3) 114 (8.1)
Treat ent technique b.001
Only balloon angioplasty 80 (9.9) 116 (9.5) 175 (12.3) 169 (12.0)
Bare-metal stenting 65 (80.0) 8 6 (66.7) 1 (8 .5) 1106 (78.4)
Drug-eluting ste ting 82 (10.1) 290 (23.8) 74 (5.2) 35 (9.6)
Stent l ngth (mm), mean ± SD 17.1 ± 6.1 18. ± 6.2 17.6 ± 5.8 17.8 ± 5.8 .003
Stent diameter (mm), mean ± SD 3.1 ± 0.5 3.0 ± 0.5 3.0 ± 0. 3.0 ± 0. .041
Procedural success 725 (92.6) 111 (91.0) 1303 (91. ) 1287 (91.4) .651
Medication
Any antithrombotic treatment prior to PCI 505 (62.7) 1054 (87.5) 1227 (86.2) 1235 (87.7) b.001
Aspiri bef re PCI 482 (59.4) 1015 (83.2) 1152 (80.9) 1 67 (82.9) b.0 1
P2Y12 inhibitor before PCI 19 (23.8) 636 (52.3) 956 (67.1) 1030 (73.2) b.0 1
Thrombolysis prior to PCI 95 (11.8) 43 (3.6) 17 (1.2) 17 (1.2) b.0 1
Glycoprotein IIb/IIIa inhibitor during PCI 400 (49.3) 657 (53.8) 570 (40.0) 334 (23.7) b.0 1
Bivalirudin during PCI – 166 (15.7) 485 (3 .1) 779 (55.3) b.0 1
668 Velders et al
American Heart Journal
May 2014
 37 
death was higher for elderly patients early after PCI, after which the prognosis 
was slightly better, compared with the general population. Long-term risk of 
adverse events increased markedly with age. 
 
Figure 9. Mortality during long-term follow-up in three different age cohorts: 70-80 years, 80-
90 years and >90 years.  
The conclusions of Paper III is that the prognosis of patients older than 80 years 
treated with primary PCI for STEMI was relatively unchanged during the 10-
year inclusion period, despite changes in patient characteristics and treatment. 
Advanced age increased the risk of adverse events and death (figure 9), but 
survivors of the early phase after PCI had a slightly improved prognosis 
compared with the general population. 
These results cannot be generalized to all patients over 80 years of age with 
STEMI, as only patients who received PCI were included in the analysis. Other 
studies23,67,68 have shown the rate of revascularization for the total octogenarian 
STEMI population to be approximately 20-30%. Hence, in Paper III one can 
assume a rather large exclusion rate. Assumingly, frail patients or those with 
serious co-morbidities were more likely to be treated conservatively.  
 
Bleeding was more common in patients older than 80
years (Figure 4B). During the first year after PCI, bleeding
rates were 3.9%, 5.3%, and 4.6% for patients aged 70 to 79
years old, 80 to 89 years old, and older than 90 years,
respectively. Multivariable analyses showed that male
gender (HR 1.72, 95% CI 1.28-2.32) and a history of
peripheral vascular disease (HR 2.17, 95% CI 1.26-3.75)
and cancer in the last 3 years (HR 1.95, 95% CI 1.13-3.38)
were associated with bleeding during the first year of
follow-up in patients 80 years or olde .
Discussion
The main findings of the present population-based
cohort study were as follows: patients with STEMI older
than 80 years treated with primary PCI during the 10-year
inclusion period generally showed a similar prognosis
over time, despite changes in patient and treatment
characteristics. Importantly, elderly patients with STEMI
showed a similar and even slightly improved long-term
survival after the e r y hase from PCI compared with the
general population. Nonetheless, the long-term risk of
adverse events increased with age, stressing the impor-
tance of appropriate risk stratification in older patients.
Elderly patients constitute a growing part of the
population presenting with STEMI, and the use of
invasive and antithrombotic therapy is increasing in
these patients.2,6 However, the impact of these de-
velopments on the prognosis remains unclear. In the
present study, the proportion of patients older than 80
years treated with primary PCI increased during the
observation period, along with a doubling of the
proportion of nonagenarians. The increase in age was
Figure 1
Mortality during long-term follow-up.
Figure 2
Relative survival of the elderly STEMI population compared with the
general population during a 3-year follow-up.
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EVALUATING BENEFIT TO THE ELDERLY POPULATION 
In general, treatment should only be provided when it is effective. Effective 
meaning that treatment can prolong life (prognostic indication) and/or decrease 
symptoms (symptom indication).  
Prognostic indication 
Underrepresentation in clinical trials and probably fear of complications in 
older patients has led to a suspected underutilization of invasive treatment in 
the elderly compared to that in younger individuals. Two main reasons are for 
the underrepresentation of elderly patients in studies, firstly, elderly patients 
simply meeting upper age criteria predefined in trials and secondly, elderly 
having higher rate of co-morbidity - and therefore have a higher risk of being 
excluded due to predefined exclusion criteria being met. Among trials 
conducted in patients with ACS published in the period 1996 to 2000, more 
than half failed to include at least one patient >75 years of age.69   
A substudy from a large randomized trial70 showed that the oldest patients 
appeared to benefit the most from the invasive treatment approach in ACS. In 
2007, the American Heart Association published a statement3 in order to 
highlight the problem of possible undertreatment in the elderly.  
The available data on efficacy of revascularization with CABG or PCI in the 
aged population with coronary artery disease mostly consist from subset 
analysis of randomized trials or non-randomized retrospective analysis, but 
during the past years two studies have been presented that are randomized 
dedicated trials to the elderly with ACS. These two studies have opposing 
results. The Italian elderly ACS study71 and the recently presented, but 
unpublished, After eighty study.  
In the Italian elderly ACS study a total of 313 ACS patients >75 years, 
excluding STEMI patients, were randomized to conservative therapy or early 
invasive therapy. This study was negative, i.e. there was no difference in the 
primary outcome (composite of death, myocardial infarction, disabling stroke, 
and repeat hospital stay for cardiovascular causes or severe bleeding) between 
the two groups.  The crossover rate (from conservative to revascularization) 
turned out to be approximately 30%. But in a subgroup with elevated troponins, 
a benefit was seen with invasive strategy.  
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The slightly larger (n=458) After eighty study (ClinicalTrials.gov Identifier: 
NCT01255540) has been presented at the American College of Cardiology 
Scientific Session conference in 2015. Among elderly patients (>80 years) with 
NSTE-ACS (ACS excluding STEMI), invasive therapy was beneficial at 
reducing adverse cardiovascular events compared with conservative therapy. 
This was mainly due to a reduction in recurrent MI and urgent revascularization 
procedures. The primary outcome of death, MI, stroke, or urgent 
revascularization occurred in 41% of the invasive group versus 61% of the 
conservative group (p < 0.0001). There were no statistical differences between 
the groups regarding death (25% vs. 27%, NS) or stroke (3% vs. 6%, NS).  
The authors of this study have concluded: "Elderly are at high risk for adverse 
events after a NSTE-ACS, and invasive therapy remains the optimal treatment 
to reduce this risk."  
Only through repeated research can certainties emerge. Interpreting and 
implementing these different study results in clinical practice can be 
challenging. In addition, the results of these trials are probably not 
generalizable to the total cohort of elderly because of the high rate of excluded 
patients. 
Currently, the clinical guidelines for the management of the elderly with ACS 
are the same as for their younger counterparts72 but with the condition that 
treatment should be individualized. These recommendations stress the 
importance of a balance between treatment risk and benefit in elderly patients. 
Symptom indication 
The invasive treatment strategy may provide unclear benefit in reducing death 
(prognostic indication) in some cohorts, the more important indication for some 
patients would be to decrease symptoms due to myocardial ischemia and thus 
increase quality of life.  Failure of the conservative strategy to be successful 
due to intolerable angina symptoms is a known problem worth mentioning, to 
some extent explaining the high crossover rate from conservative therapy to 
invasive therapy in randomized trials. In addition, cost-effective analysis for 
elderly with stable coronary artery disease has shown that early increased costs 
of revascularization in invasive patients were balanced after one year by 
increased medical charges and symptom-driven late revascularizations in 
medical patients. Therefore, the invasive strategy had improved clinical 
effectiveness (in stable coronary disease) at only marginally higher cost 
compared to medical management.73 
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Among elderly individuals, the generally lower level of physical activity results 
in less myocardial oxygen demand and hence, one would expect less angina 
symptoms. In elderly patients with presumed high-risk for periprocedural PCI 
complications and unclear benefit, initiating conservative therapy with the 
possibility of shifting the treatment strategy based on the patients symptoms, 
would be a reasonable approach. 
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SHARED DECISION MAKING 
 
"Medicine is not only a science; it is also an art. It does not consist of 
compounding pills and plasters; it deals with the very processes of life, which 
must be understood before they may be guided." 
-Paracelsus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. A pair of feet standing on a tarmac road with yellow arrow print pointing in three 
different directions for the concept of making decision at the crossroad. Photo by Gwoeii. 
<www.shutterstock.com> 
 
Patients should be able to make choices in their care that best fit their individual 
circumstances. Health care providers should have the time and communication 
skills to elicit their patients’ wishes, needs and concerns. Breakdowns in the 
patient-doctor relationship can occur when the patient feels that he/she has 
received too little information and the physician has rushed through the 
encounter. Communicating effectively in challenging situations like helping 
patients make complex choices in circumstances of medical uncertainly or 
breaking bad news should be regarded as a part of continuing professional 
development. Unfortunately, opportunities rarely exist for practicing physicians 
to develop new communication skills or to receive systematic feedback. 
Communication skills are a learned expertise; that allows clinicians to fulfill 
their clinical and moral responsibilities to patients. Physicians usually 
acknowledge acquiring new technical skills or information about different 
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treatments as a part of professional career evolvement, but frequently fail to 
recognize communication skills as such. We must change our thinking about 
this fundamental obligation. The importance of incorporating the patient in a 
shared decision making process must be stressed, and if done effectively-
success in terms of increased patient satisfaction and trust will be the outcome, 
even in patients with limited treatment options.  
Treatment outcome is a strong determinant of patients’ preferences. In one 
study, of seriously ill older patients, the burden of treatment, its outcomes, all 
influenced the treatment preferences.74 Almost all study participants chose a 
low-burden therapy (short hospital time, less diagnostic testing and less 
invasive interventions) that would restore their current health. However, for a 
low-burden treatment with less chance for good functional or cognitive 
outcome, almost all of the participants stated that they would not wish to 
receive such a therapy.  
Life expectancy and treatment outcomes play a dominant role in the final 
decision making process among elderly patients. The outcome of such 
discussions may be having comfort care as the treatment goal, instead of 
continuing with treatment with potential harm, and unknown benefit. 
Previous research has indicated that many hospital admissions in the elderly 
can be avoided and may be inappropriate.75,76 A series of complex reasons, 
including factors associated to the physician, the patient and the family, are 
usually given for this. Denial about prognosis can lead to predictable crises and 
potentially avoidable emergency visits. Underlying reasons for unnecessary 
admissions often being the failure to recognize approaching death at the 
appropriate time and thus to shift treatment towards maintaining comfort or 
palliative care. Knowing our patients’ priorities, and acting to fulfill these, will 
lead to a better quality of life, or among those beyond cure - quality of death. 
Too risky or simply too old? 
Unfortunately, in the absence of sound evidence, clinical decisions can be 
strongly influenced by the stereotypic and often negative perception of 
physicians who have previously treated elderly patients with complications. 
Some would argue this to be good clinical judgment based on "experience". But 
these stigmas can result in deleterious consequences for people in normal 
aging- with risk for discrimination based on chronological age. The perception 
of aging among health professionals has been found to be negative but 
physicians and nurses with experience and interest in geriatric care, more senior 
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in position, and those with elderly social contacts were found to have a more 
positive attitude towards the elderly.77-79 
There is no simple solution to counter ageism among health professionals, but 
gerontology education and training has been shown to enhance positive 
attitudes toward elderly patients.80,81 
In the ideal world, all health care providers will have the training and team 
support to manage the expanding elderly population with complex diseases and 
treatment. 
Upcoming studies  
There are some studies of the elderly with ACS in the pipeline, trials designed 
to try to answer the question of benefit and risks with each treatment strategy 
(conservative or invasive), two trials are discussed below. 
The Revascularization or Medical Therapy in Elderly Patients With Acute 
Angina Syndromes (RINCAL) (ClinicalTrials.gov Identifier: NCT02086019) is 
a randomized controlled trial in patients >80 years of age with NSTEMI, with 
both elevated Troponins and ECG with ischemic changes. The estimated 
number of study participants is 750 and they will be randomized to invasive or 
conservative therapy. The primary outcome measure is 1-year mortality and 1-
year non-fatal myocardial infarction. The study was initiated by the Brighton 
and Sussex University Hospitals and started to recruit patients in May 2014 
with estimated completion year 2019.  
The Octogenarians study (Paper IV) 
Another upcoming study is described in Paper IV,82 the Octogenarians study 
(ClinicalTrials.gov Identifier: NCT02126202). This study is a multicenter; 
investigator initiated randomized controlled trial of patients ≥80 years old with 
two parallel treatment arms, a medical group and an invasive group. 
Participating hospitals are: Sahlgrenska University Hospital in Gothenburg, 
Norra Älvborg Regional Hospital in Trollhättan, Skåne University Hospital in 
Lund, and Skaraborg Hospital in Skövde. In total, 200 patients with non-ST-
elevation myocardial infarction or unstable angina will be randomized to 
medical or invasive treatment strategy. Due to risk for unbalanced treatment 
arms regarding age, two different predefined strata (80-84 and ≥85 years of 
age) will be used for random assignment. 
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Table 6. Schedule of enrollment, interventions, assessments, and outcome/safety 
measures for the Octogenarian study 
According to power calculations, with α level <0.05, 80% power and expected 
major adverse cardiac or cerebrovascular event  (MACCE) rate according to the 
TACTICS-TIMI 18 study70 there will be required 82 individuals in each group. 
Due to possible dropout, a total of 200 patients will be included. The study 
started in 2009 and is still recruiting patients. The schedule of enrollment, 
interventions, assessments, and outcome/safety measures for the study are 
shown in table 6. The primary outcome measure is the combined endpoint 
MACCE within 1 year. Other outcome and safety measures are grade of angina, 
quality of life, frailty and bleeding. 
This study seeks to determine the efficacy and safety of invasive and medical 
treatment strategies in the elderly with ACS. Our hypothesis is that invasive 
treatment of elderly patients with ACS will lead to better outcome in terms of 
survival and quality of life than medical therapy alone, with acceptable risk. 
order to ensure validity and integrity. The statistical ana-
lysis will be managed according to the intention-to-treat
principle.
Discussion
This study seeks to determine the efficacy and safety of
invasive and medical treatment strategies in elderly pa-
tients with ACS. In doing so, the study will advance our
understanding of therapy choice in elderly patients with
ACS. The different treatment strategies have the p ten-
tial to reduce angina pectoris and complications, and
improve quality of life and survival.
Trial status
Recruitment to the study commenced in October 2009
and is still continuing to recruit patients. The recruit-
ment of all patients will hopefully be finished in year
2015.
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HIGH RISK GROUPS 
Cardiogenic shock 
Acute coronary syndrome accounts for approximately 75% of those with 
cardiogenic shock (CS). The incidence of 6-8% within the ACS population has 
been relatively unchanged during the past years,35 but is higher among the 
elderly as they turn out to have poor organ reserve and can have difficulties in 
tolerating stress. In Paper III, among elderly patients with STEMI treated with 
PCI the incidence of CS was 9,7% years 2001-2004 but decreased to 4,5% 
years 2009-2010.  
The mortality is high, especially in elderly patients, 65-80%.83,84 The most 
common cardiac etiology for CS is left ventricular failure, but other causes are 
papillary muscle rupture, severe mitral valve insufficiency, ventricular septal 
defect, and free wall rupture. 
Because revascularization is the cornerstone of the treatment in patients with 
cardiogenic shock complicating ACS, emergency coronary angiography is 
indicated according to the guidelines.35 But, there have been conflicting results 
regarding the benefit of early revascularization of elderly patients with CS. In 
the SHOCK study85 subgroup analysis showed no benefit from early 
revascularization in patients >75years, but this result was only based on 56 
elderly patients, with unbalanced treatment groups in regards to congestive 
heart failure, thus there was risk for underpowered and biased study results. 
Observational studies have shown that the early revascularization is associated 
with better outcome compared to conservative therapy, but observational 
studies carry risk for selection bias.86,87 
There are no existing registered (Clinical trials.gov) dedicated trials of 
cardiogenic shock in the elderly.  
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Cardiac arrest (Paper V) 
Another important group with very high mortality among ACS patients are 
patients with cardiac arrest. Approximately 70% of those with out-of-hospital 
cardiac arrest have coronary artery disease with acute coronary occlusion 
observed in 50%.88 
In resuscitated cardiac arrest patients, neurological recovery is the most critical 
issue. In case of cardiac arrest, qualitative reports 10,89 have shown that elderly 
people are mainly concerned about loss of autonomy, and about whether they 
would be able to return to their valued life activities. This is why, in studies of 
elderly patients, one should not only concentrate on survival rates but also on 
inclusion of other outcome measures―such as neurological outcome, which is 
one factor that really matters for patients and their families. 
Earlier studies on hospitalized elderly victims of cardiac arrest have shown 
poor prognosis.90-92 These data were unfortunately extrapolated to all elderly 
patients by medical professionals and also by the lay press. They included 
sudden death victims in the community, leading to the incorrect assumption that 
efforts to resuscitate elderly people were futile and should be withheld. More 
recent studies have shown that the prognosis for the elderly with OHCA is 
improving as time goes by, with higher survival rates. 93-95  
The aim Paper V was to evaluate an elderly population of OHCA victims, to 
analyze temporal trends, and to determine whether there were age-related 
differences in outcome (30-day survival and cerebral performance category 
score).   
Elderly OHCA patients (≥ 70 years), who were registered in the Swedish 
Cardiopulmonary Resuscitation Register, between 1990 and 2013 were 
included and divided into three age categories (70‒79, 80‒89, and ≥ 90 years). 
Their baseline characteristics are shown in table 7 and the factors associated 
with 30-day survival are shown in table 8. 
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Table 7. Baseline characteristics of elderly OHCA patients 
 
!
Table 1     Baseline characteristics 
__________________________________________________________________________________ 
                                                Age (years) 
  70-79           80-89            ≥ 90 
 (n=19422)  (n=14710)  (n=2473)           p 
__________________________________________________________________________________ 
Age (median; years)    75    83 92  
Gender (%) (3, 2, 2)*  
 Women  30 38 56 <0.0001 
Etiology (%) (6, 7, 7) *  
 Cardiac 77 78 71   0.20 
Place (%) (0.8, 0.7, 0.7) *  
 At home  69 68 70   0.78           
Witnessed (%) (6, 6, 5) *     <0.0001     
By crew  14 18 22  
 By a bystander 57 55 54 
 Non witnessed 29 27 24  
Initial arrhythmia (%) (9, 10, 10)*  
 Ventricular fibrillation 31 25 16 <0.0001 
Bystander CPR (%)(2, 1, 1)*  
 Yes 45 42 45 <0.0001 
30-day survival (%)(0.4, 0.5, 0.6)*  
 All patients   6.6   4.4 2.3 <0.0001 
 Witnessed, cardiac etiology found 19.8 14.8 11.0 <0.0001 
 in VF†  
Delay times (min) (2, 0.3, 1)*          
 Call for – Arrival of EMS††   7 (9.5)**   7 (9.1)   7 (9.2) <0.0001 
 (13,14,17)* 
 Collapse – Call for EMS (21,23,27)*  3 (5.0)   3 (4.8)   3 (4.5)   0.0001 
 Collapse – Start of CPR# (18,19,20)*    9 (10.7)    8 (10.1)   7.5 (9.1) <0.0001 
*   Proportion of patients with missing information 
** Median and mean within brackets                          
†   VF = Ventricular fibrillation  †† EMS = Emergency Medical Service   
#   CPR = Cardiopulmonary resuscitation 
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Table 8. Factors associated with 30-day survival 
 
 
 
 
! 2!
Table 2 
Factors associated with 30-day survival  
___________________________________________________________________________ 
        OR               Adjusted OR* 
 
Age (years; continuous)   0.95 (0.94 – 0.96)     0.94 (0.93 – 0.96) 
SEX 
 Women/ men   0.75 (0.68 – 0.83) --- 
PLACE 
 At home (yes/no)   0.28 (0.25 – 0.30) 0.40 (0.34 – 0.46) 
Witnessed 
 Yes/no   5.05 (4.26 – 6.03) 2.20 (1.79 – 2.72) 
Bystander CPR* 
 Yes/no   2.87 (2.54 – 3.25) 1.84 (1.58 – 2.14) 
First recorded rhythm 
 Ventricular fibrillation (yes/no) 10.04 (8.97 – 11.25) 5.86 (5.00 – 6.88) 
Delay Call for – arrival of EMS* 
 Continous, logaritmised   0.38 (0.34 – 0.42) 0.38 (0.33 – 0.43) 
   
__________________________________________________________________________ 
*  Crew witnessed cases were excluded  Adjusted(OR(for(age,(gender,(cardiac(etiology,(place,(witnessed(status,(bystander(CPR,(initial(rhythm(and(EMS(response(time.((
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Figure 11. Changes in survival in relation to age from 1992 to 2013 
 
 
Figure 12. Estimated cerebral function according to CPC score among survivors of OHCA in 
relation to age. Missing rate and the number of evaluated cases were:  70-79 years 28%, n=339, 
80-89 years 25%, n=192 and ≥90 years 27%, n=27 
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Altogether, 36,605 cases were included in the study. The 30-day survival was 
6.6% in patients aged 70‒79 years, 4.4% in patients aged 80‒89 years, and 
2.3% in those over 90 years. The results depending on different time periods 
are shown in figure 11. In 30-day survivors, the distribution according to the 
cerebral performance categories (CPC) score at discharge from hospital was 
similar in the three age groups (figure 12). The following conclusions were 
reached in Paper V, advanced age turned out to be an independent predictor of 
mortality in OHCA patients over 70 years of age. However, even in patients 
above 90 years of age, defined subsets with a survival rate of more than 10% 
existed. In survivors, the neurological outcome remained similar regardless of 
age. 
Regarding CPR for cardiac arrest, therapy must be applied promptly and 
without hesitation, in order to have any chance of success. It would be unfair to 
put a difficult ethical decision burden on rescuers regarding whether or not to 
start CPR in the case of sick or frail elderly patients. Even though discussions 
regarding the end of life are challenging and emotionally charged, clinicians 
should take time to discuss them with patients. The preferences of patients and 
their proxies in combination with information about expected outcome should 
form the basis of end-of-life decisions. DNR (Do-not-resuscitate) orders should 
not be regarded as markers of death, but rather the result of informed discussion 
about end-of-life care.  
In Paper V, the survival rates for the elderly with OHCA were determined 
according to age and, the cardiac arrest characteristics that predicted survival. 
We did not have information about pre-arrest diseases in our analysis. In order 
to guide DNR decisions, other factors that poorly affect outcome―such as pre-
arrest co-morbidity―should be taken into consideration. This has proven to be 
a difficult task. A meta-analysis failed to do so, mainly due to the heterogeneity 
of the studies included.96 A step-by-step approach as previously described, 
taking into consideration life expectancy, risk, benefit and patient or their 
proxies’ preferences would also be possible to apply during end-of-life 
decision-making.  
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CHALLENGES IN GERIATRIC RESEARCH  
 
 
 
 
 
 
 
 
 
 
Figure 13. There exist different challenges in research of the elderly population. Illustration by 
the author 
Patient selection and risk for bias  
The effect of a treatment strategy in heterogenic patient groups is very difficult 
to evaluate. One cannot eliminate the possibility of the difference in outcome 
being simply due to differences in baseline characteristics within the study 
population. When examining treatment effects, comparing interventions head to 
head within subpopulations, such as the elderly, heterogeneity among patients 
with multiple chronic conditions complicates research. Heterogeneity of study 
participants would be especially problematic in observational studies. This is 
called different names such as: selection bias, bias by indication, confounding 
by indication or poor internal validity. Even though adjustments can be made 
for known confounding factors -unknown confounding factors are more 
difficult to tackle, one important, but not always accounted for is frailty.  
Frailty could turn out to be useful for risk stratification of the elderly 
population, thus being a valuable tool to compensate for the heterogeneity in 
the group of elderly, and in doing so, correct for potential confounding or bias. 
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Unfortunately, information about frailty is lacking in many databases, analysis 
and published studies, but has on the other hand been gaining more 
acknowledgements in the recent years. 
But this complexity of elderly patients in studies argues for adapting research 
designs to the important study questions. This fastest growing segment of 
complex patients within health care should not be ignored.  
Patient recruitment 
Even though the population of elderly patients is large and constantly growing, 
randomized controlled clinical trials are very difficult to perform in the elderly 
population, although this research design is considered the most valuable.  
One of the common problems encountered by research teams are geriatric 
patient recruitment and retention issues. Major barriers to recruitment of older 
adults in research relate to their co-morbidity, limited life expectancy, frequent 
hospitalizations, polypharmacy, social barriers, and potentially impaired 
capacity to provide informed consent. Researchers, often appropriately, may be 
concerned about the safety or risk of study procedures. Elderly individuals are 
likelier to be excluded from clinical trials explaining the lower average age in 
study participants compared to real life patients. Some reasons that may justify 
this approach are: avoiding attrition (high mortality, risk for general health 
decompensation, cognitive impairment, impaired mobility), minimizing 
confounding due to competing risks, avoiding longer study visits due to hearing 
or sight impairments. In addition, many randomized studies have upper age 
limits or long lists of exclusion criteria making it impossible for elderly patients 
to enter.  But if the aim of the study is to generalize results to older adults with 
complex health problems, the inclusion and exclusion criteria must be designed 
to allow their participation. 
Because elderly hospitalized patients may have complex situations, family 
members or friends are often involved as a substitute decision-maker during 
enrollment in studies. Proxies may understandably be protective and skeptical 
about any research project that might add burden to an already difficult 
situation. 
The problem, in general, with dedicated randomized studies in the elderly has 
been recruiting issues, slow and difficult enrollment. Unfortunately, this has 
resulted in study centers simply giving up and some studies terminating early 
without results. 
 53 
Some of these challenges can be overcome with some practical approaches: 
eliminating upper age limits in studies, minimizing exclusion criteria, timely 
screening, keeping interest and cooperation of study sites, ensuring a favorable 
risk: benefit ratio of study participants, choosing an adequate but not too large 
sample size, and addressing problems of study participants who consider to 
dropout (such as need for assistance or travel cost). 
Challenging data analysis and interpretation of results 
Most clinical research projects in medicine focus on the disease-oriented 
approach, which does not take account of the complexity of the typical elderly 
patient. In most of the randomized clinical trials, sample size, duration, and co-
prescribed drug therapies are often tailored to the target disease but issues in the 
elderly such as quality of life; short life expectancy, polypharmacy, and 
multimorbidity are not accounted for. 
Randomization and the intention-to-treat analysis of data, if successful, would 
divide confounding factors equally in both groups being studied thus 
eliminating most bias. But, if treatment groups are unbalanced by chance, study 
participants are misclassified (for example without the studied disease) or if 
there is large crossover to the other parallel treatment group, then the results 
can be very difficult or impossible to interpret. 
Non-adherence to study protocols such as in phase 3 drug trials, due to limited 
tolerability of treatment, is a problem commonly encountered among the 
elderly. This would lead to loss of study participants that might be difficult to 
account for. 
Some of the larger randomized trials also have results from post-hoc subgroup 
analysis of the elderly within the study population. Interpretations of results 
from secondary and subgroup analyses are useful for hypothesis generation, but 
are usually underpowered, too often misleading, and may be based on chance 
findings alone. 
Crossover to the other treatment arm, such as in studies of invasive or 
conservative treatment for ACS, is another known potential problem. 
Observational data in elderly patients support the power of clinical judgment 
compared with unselective use of invasive treatment. The reality may be that 
the randomization cannot account for the importance of clinical judgment in 
achieving best outcomes in the complex elderly. 
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AGE IS OPPORTUNITY 
"Age is opportunity no less,  
Than youth itself, though in another dress 
And as the evening twilight fades away, 
The sky is filled with stars, invisible by day." 
                       -Henry Longfellow 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. A beautiful green and red aurora dancing over the Jökulsárlón lagoon, Iceland. 
Photo by Krissanapong Wongsawarng. <www.shutterstock.com> 
Despite risk associated with treatment in complex elderly patients, these 
individuals have the greatest potential for clinical benefit due to high risk for 
mortality and morbidity - compared to younger, healthier subjects. 
We should not assume that age is a non-modifiable risk for worse outcomes. 
We need to understand the biological and social factors that result in poor 
outcomes for our elderly and develop systems of care capable of addressing 
these issues. Our perception of what constitutes “old” is continually changing. 
This has been exemplified by the progress we have achieved in providing 
cardiovascular care to this growing and constantly older set of patients. 
In cardiology, our services could be provided with reasonable risks and with 
potentially much gain to the elderly. Advancements in the delivery of care have 
permitted us to apply valuable, life-preserving techniques to the geriatric 
population. Future investigations should continue to challenge age-related 
discrimination against treating patients, demanding rigorous investigation into 
the factors that impair quality and quantity of life.  
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SWEDISH SUMMARY 
Den äldre patientgruppen är snabbt växande inom sjukvården. Hur denna grupp 
skall behandlas är ofta ett kliniskt dilemma då denna patientgrupp är dåligt 
studerad och såväl kvaliteten som kvantiteten av underliggande vetenskapliga 
bevis är begränsad. 
I denna avhandling presenteras fem olika studier som undersöker olika aspekter 
av hjärtsjukvård avseende patienter av hög ålder. 
I delarbete I beskrivs skillnader mellan äldre och yngre patienter med symtom 
(framförallt bröstsmärta) tydande på akut kranskärlssjukdom. Studien visar att 
trots att äldre patienter (> 80 år) oftare får en slutlig diagnos av akut koronart 
syndrom (17 % vs 8 %), blir de mer sällan undersökta med kranskärlsröntgen 
(44 % vs 89 %, p <0,0001) och ekokardiografi än de yngre patienterna. De 
äldre patienterna får dessutom i lägre utsträckning medicinsk behandling med 
blodförtunnande och blodfettsänkande läkemedel. Däremot påvisas ingen 
fördröjning till sjukhusinläggning jämfört med yngre. Att äldre patienter i lägre 
grad får evidensbaserad behandling kan sannolikt förklaras att man värderar att 
risken ofta överväger nyttan för denna patientgrupp, även om detta inte är 
verifierat i studier.  
I delarbete II studeras äldre (>75år) patienter med hjärtinfarkt. De som valts ut 
för invasiv strategi (kranskärlsröntgen eventuellt följt av intervention) jämförs 
med den grupp som behandlats konservativt (medicinsk behandling). Det var en 
högre andel patienter med hjärtsvikt, både i anamnesen och vid ankomsten, i 
den konservativa gruppen jämfört med den invasiva gruppen. Det var lägre 
sjukhusdödlighet i den invasiva gruppen (9 % vs 20 %, p <0,0003). Man kan 
inte dra slutsatsen att invasiv strategi generellt är bättre då det var stora 
skillnader i bakgrundsvariabler mellan grupperna. En randomiserad studie 
behövs för att man skall kunna dra en slutsats vilken strategi som är bäst för de 
äldre patienterna. Ett protokoll för en sådan pågående studie diskuteras i 
delarbete IV. 
I delarbete III, studeras äldre (> 80 år) patienter med STEMI som behandlats 
med PCI under en 10-års studieperiod. Medelålder och co-morbiditet ökade 
successivt under åren men trots detta var utgången oförändrad. Dessutom var 
komplikationsrisken i form av blödning, hjärtinfarkt, hjärtsvikt och stroke 
oförändrad under studieperioden.  
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I delarbete V, stratifierades patienter över 70 år som drabbats av hjärtstopp 
utanför sjukhus, i tre olika åldersgrupper: 70-79, 80-89 och ≥90 år. Med 
stigande ålder minskade chansen för 30-dagars överlevnad. Däremot var ålder 
var inte en avgörande faktor för dåligt neurologisk resultat efter hjärtstopp. 
Samma faktorer (t.ex. bevittnat hjärtstopp och defibrillerbar första rytm) som 
visat sig vara associerad med bättre prognos i yngre kohorter, var även 
gynnsamma för de äldre grupperna.  
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